Abstract
Background/Aims: Both proton pump inhibitor (PPI) and histamine-2-receptor antagonist (H2RA) are considered to be effective for the treatment of iatrogenic gastric ulcer after endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD). We aimed to systematically evaluate the evidence comparing PPI and H2RA for iatrogenic ulcer. Methods: Data from PubMed, Cochrane Library and Google Scholar were searched to identify eligible randomized trials. Outcome measures were delayed bleeding, epigastric pain and ulcer healing. Results: Six full-text studies were identified including a total of 522 patients. Pooled data suggested a significantly lower bleeding rate in the PPI group than in the H2RA group (odds ratio (OR) 0.49, 95% confidence interval (CI) 0.25-0.95). Subgroup analysis showed PPI was more effective in the prevention of bleeding than H2RA for ESD-induced ulcer (OR 0.41, 95% CI 0.20-0.85) and 8-week duration of medication (OR 0.36, 95% CI 0.17-0.76). There were no differences in the incidence of epigastric pain (OR 0.90, 95% CI 0.53-1.51) and ulcer healing rate after endoscopic therapies between both groups. Conclusion: This meta-analysis shows PPI is superior to H2RA for the prevention of delayed bleeding without different effectiveness in the reduction of epigastric pain and in the promotion of ulcer healing after EMR or ESD.
Journal Section:
Original Paper
References
1.
Kantsevoy SV, Adler DG, Conway JD, Diehl DL, Farraye FA, et al: ASGE Technology Committee: Endoscopic mucosal resection and endoscopic submucosal dissection. Gastrointest Endosc 2008;68:11-18.
[PubMed]
2.
Neuhaus H: Endoscopic mucosal resection and endoscopic submucosal dissection in the West - too many concerns and caveats? Endoscopy 2010;42:859-861.
[PubMed]
3.
Yamamoto H: Technology insight: endoscopic submucosal dissection of gastrointestinal neoplasms. Nat Clin Pract Gastroenterol Hepatol 2007;4:511-520.
[PubMed]
4.
Lee JH, Kim JJ: Endoscopic mucosal resection of early gastric cancer: experiences in Korea. World J Gastroenterol 2007;13:3657-3661.
[PubMed]
5.
Chang CC, Lee IL, Chen PJ, Wang HP, Hou MC, Lee CT, et al: Endoscopic submucosal dissection for gastric epithelial tumors: a multicenter study in Taiwan. J Formos Med Assoc 2009;108:38-44.
[PubMed]
6.
Isomoto H, Yamaguchi N: Endoscopic submucosal dissection in the era of proton pump inhibitors. J Clin Biochem Nutr 2009;44:205-211.
[PubMed]
7.
Cao Y, Liao C, Tan A, Gao Y, Mo Z, Gao F: Meta-analysis of endoscopic submucosal dissection versus endoscopic mucosal resection for tumors of the gastrointestinal tract. Endoscopy 2009;41:751-757.
[PubMed]
8.
Higgins JPT, Green S (eds): Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.2 (Updated September 2009). The Cochrane Collaboration 2009. Available at: www.cochrane-handbook.org (accessed on September 29, 2009).
9.
Ye BD, Cheon JH, Choi KD, Kim SG, Kim JS, Jung HC, et al: Omeprazole may be superior to famotidine in the management of iatrogenic ulcer after endoscopic mucosal resection: a prospective randomized controlled trial. Aliment Pharmacol Ther 2006;24:837-843.
[PubMed]
10.
Sakita T, Fukutomi H: Endoscopic diagnosis; in Yoshitoshi Y (eds): Ulcer of Stomach and Duodenum (in Japanese). Tokyo, Nankodo, 1971, pp 198-208.
11.
Esaki M, Aoyagi K, Matsumoto T, Kuwano Y, Shimizu M, Fujishima M: Effects of omeprazole and famotidine on fibroblast growth factor-2 during artificial gastric ulcer healing in humans. Eur J Gastroenterol Hepatol 2002;14:365-369.
[PubMed]
12.
Yamaguchi Y, Katsumi N, Tauchi M, Toki M, Nakamura K, Aoki K, et al: A prospective randomized trial of either famotidine or omeprazole for the prevention of bleeding after endoscopic mucosal resection and the healing of endoscopic mucosal resection-induced ulceration. Aliment Pharmacol Ther 2005;21(suppl 2):111-115.
[PubMed]
13.
Uedo N, Takeuchi Y, Yamada T, Ishihara R, Ogiyama H, Yamamoto S, et al: Effect of a proton pump inhibitor or an H-2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer: a prospective randomized controlled trial. Am J Gastroenterol 2007;102:1610-1616.
[PubMed]
14.
Jeong HK, Park CH, Jun CH, Lee GH, Kim HI, Kim HS, et al: A prospective randomized trial of either famotidine or pantoprazole for the prevention of bleeding after endoscopic submucosal dissection. J Korean Med Sci 2007;22:1055-1059.
[PubMed]
15.
Ohya TR, Endo H, Kawagoe K, Yanagawa T, Hanawa K, Ohata K, et al: A prospective randomized trial of lafutidine vs. rabeprazole on post-ESD gastric ulcers. World J Gastrointest Endosc 2010;2:36-40.
[PubMed]
16.
Hashimoto T, Adachii K: Changes in gastric mucosal blood flow during healing of EMR-induced ulcer: comparison with peptic ulcer. Dig Endosc 1997;9:127-131.
17.
Oh JH, Choi MG, Dong MS, Park JM, Paik CM, Cho YK, et al: Low-dose intravenous pantoprazole for optimal inhibition of gastric acid in Korean patients. J Gastroenterol Hepatol 2007;22:1429-1434.
[PubMed]
18.
Lee SY, Kim JJ, Lee JH, Kim YH, Rhee PL, Paik SW, et al: Healing rate of EMR-induced ulcer in relation to the duration of treatment with omeprazole. Gastrointest Endosc 2004;60:213-217.
[PubMed]
19.
Abe Y, Inamori M, Togawa J, Kikuchi T, Muramatsu K, Chiguchi G, et al: The comparative effects of single intravenous doses of omeprazole and famotidine on intragastric pH. J Gastroenterol 2004;39:21-25.
[PubMed]
20.
Oh TH, Jung HY, Choi KD, Lee GH, Song HJ, Choi KS, et al: Degree of healing and healing-associated factors of endoscopic submucosal dissection-induced ulcers after pantoprazole therapy for 4 weeks. Dig Dis Sci 2009;54:1494-1499.
[PubMed]
21.
Jeon SW, Jung MK, Cho CM, Tak WY, Kweon YO, Kim SK, et al: Predictors of immediate bleeding during endoscopic submucosal dissection in gastric lesions. Surg Endosc 2009;23:1974-1979.
[PubMed]
22.
Ueda H, Ito M, Tanaka S, Oka S, Takata S, Imagawa S, et al: The effect of Helicobacter pylori eradication therapy on gastric ulcer healing after endoscopic mucosal resection. J Clin Gastroenterol 2006;40:293-296.
[PubMed]
23.
Kakushima N, Fujishiro M, Yahagi N, Kodashima S, Nakamura M, Omata M: Helicobacter pylori status and the extent of gastric atrophy do not affect ulcer healing after endoscopic submucosal dissection. J Gastroenterol Hepatol 2006;21:1586-1589.
[PubMed]
24.
Kawano S, Okada H, Hori K, Tanioka D, Kita M, Tsuzuki T, et al: Comparison of healing rate of artificial ulcer after endoscopic submucosal dissection in relation to the dose of proton pump inhibitor: a prospective randomized controlled trial. Gastroenterology 2008;134:A-611.
25.
Watanabe Y, Kato N, Maehata T, Okamoto M, Tsuda T, Hattori S, et al: Safer endoscopic gastric mucosal resection: preoperative proton pump inhibitor administration. J Gastroenterol Hepatol 2006;21:1675-1680.
[PubMed]
26.
One S, Kato M, One Y, Nakagawa M, Naka-gawa S, Shimizu Y, et al: Effects of preoperative administration of omeprazole on bleeding after endoscopic submucosal dissection: a prospective randomized controlled trial. Endoscopy 2009;41:299-303.
[PubMed]
27.
Kato T, Araki H, Onogi F, Ibuka T, Sugiyama A, Tomita E, et al: Clinical trial: rebamipide promotes gastric ulcer healing by proton pump inhibitor after endoscopic submucosal dissection - a randomized controlled study. J Gastroenterol 2010;45:285-290.
[PubMed]
28.
Asakuma Y, Kudo M, Matsui S, Okada M, Kawasaki M, Umehara Y, et al: Comparison of an ecabet sodium and proton pump inhibitor (PPI) combination therapy with PPI alone in the treatment of endoscopic submucosal dissection-induced ulcers in early gastric cancer: prospective randomized study. Hepatogastroenterology 2009;56:1270-1273.
[PubMed]
29.
Inaba T, Ishikawa S, Toyokawa T, Ishikawa H, Miyahara K, Wato M, et al: Basal protrusion of ulcers induced by endoscopic submucosal dissection during treatment with proton pump inhibitors, and the suppressive effects of polaprezinc. Hepatogastroenterology 2010;57:678-684.
[PubMed]
© 2011 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2011
You do not currently have access to this content.
